Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Lilly announced meaningful price cuts to its tirzepatide-based obesity drug Zepbound, reducing out-of-pocket costs on its LillyDirect platform to as low as $299 for the starter dose and $449 for higher doses, just weeks after negotiating a separate price-cut agreement with the Trump Administration to secure Medicare access and tariff relief
Ultimately, this is not just an operational issue delays in securing manufacturing capacity can directly erode programme value by pushing out launch timelines and impacting revenue realisation
A scoping review on long COVID-19: physiological and psychological symptoms post-acute, long-post and persistent post COVID-19
Consult your doctor before making changes
SheMed begins with a thorough clinical assessment which includes blood testing before prescribing anything
US$ 22.67
US$ 28.80
US$ 28.71
US$ 25.85
US$ 26.49
